Transarterial
chemoembolization
(TACE) has emerged as the mainstay treatment for patients suffering
from unresectable intermediate hepatocellular carcinoma and also holds
the potential to treat other types of hypervascular cancers such as
renal cell carcinoma. However, an in vitro model
for evaluating both embolic performance and drug-release kinetics
of the TACE embolic agents is still lacking since the current models
greatly simplified the in vivo vascular systems as
well as the extracellular matrices (ECM) in the organs. Here, we developed
a decellularized organ model with preserved ECM and vasculatures as
well as a translucent appearance to investigate chemoembolization
performances of a clinically widely used embolic agent, i.e., a doxorubicin-loaded
ethiodised oil (EO)-based emulsion. We, for the first time, utilized
an ex vivo model to evaluate the liquid-based embolic
agent in two organs, i.e., liver and kidneys. We found that the EO-based
emulsion with enhanced stability by incorporating an emulsifier, i.e.,
hydrogenated castor oil-40 (HCO), showed an enhanced occlusion level
and presented sustained drug release in the ex vivo liver model, suggesting an advantageous therapeutic effect for TACE
treatment of hepatocellular carcinoma. In contrast, we observed that
drug-release burst happened when applying the same therapy in the
kidney model even with the HCO emulsifier, which may be explained
by the presence of the specific renal vasculature and calyceal systems,
indicating an unfavorable effect in the renal tumor treatment. Such
an ex vivo model presents a promising template for
chemoembolization evaluation before in vivo experiments
for the development of novel embolic agents.